Showing results (411-420 of 427) with videos related to
Sort By:
Pageof 43
American Journal of Hematology|December 18, 2023
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohortCarmelo Gurnari, Maria Rosaria Pascale, Antonio Vitale, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2023
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)Esther Natalie Oliva, Marta Riva, Pasquale Niscola, et al.Cancer|May 12, 2026
Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world studyFrancesca Palandri, Monia Marchetti, Elena M Elli, et al.Hematological Oncology|May 9, 2025
Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient PopulationMassimo Breccia, Antonella Russo Rossi, Valentina Giai, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2016
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 TrialUwe Platzbecker, Giuseppe Avvisati, Laura Cicconi, et al.Frontiers in Oncology|September 13, 2021
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA NetworkGiorgina Specchia, Patrizia Pregno, Massimo Breccia, et al.Cancer|June 29, 2025
Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML CampusValentina Giai, Tiziana Rosso, Fausto Castagnetti, et al.Annals of Hematology|March 4, 2024
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment optionsJean-Jacques Kiladjian, Francisca Ferrer Marin, Haifa Kathrin Al-Ali, et al.Blood Advances|December 5, 2025
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351Raffaele Palmieri, Fabio Guolo, Luana Fianchi, et al.British Journal of Haematology|October 12, 2021
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML reportMassimo Breccia, Elisabetta Abruzzese, Vincenzo Accurso, et al.Pageof 43